Bile acid-induced negative feedback regulation of the human ileal bile acid transporter.
paper
Cited
Public
Unavailable
- Authors
- Neimark, Ezequiel; Chen, Frank; Li, Xiaoping; Shneider, Benjamin L
- Year
- 2004
- Journal
- Hepatology (Baltimore, Md.)
- PMID
- 15239098
- DOI
- 10.1002/hep.20295
Ileal expression of the apical sodium-dependent bile acid transporter (ASBT) in the rat is unaffected by bile salts, yet in the mouse it is under negative-feedback regulation. The bile acid responsiveness of human ASBT is unknown. The human ASBT promoter linked to a luciferase reporter was studied in Caco-2 cells treated with chenodeoxycholic acid (CDCA) and transfected with expression plasmids for farnesoid X-receptor (FXR), short heterodimer partner (SHP), and retinoic acid receptor/retinoid X receptor (RAR/RXR). CDCA treatment of Caco-2 cells led to a 75% reduction in steady-state ASBT messenger RNA levels and a 78% reduction in human ASBT promoter activity. A dominant negative FXR abrogated the response to CDCA. Site-directed mutagenesis of an RAR/RXR cis element in the human ASBT promoter reduced its activity by 50% and eliminated the bile acid response. Retinoic acid activated the human ASBT promoter fourfold. SHP repressed the activity of the ASBT promoter and reduced activation by retinoic acid. Antisense mediated knock-down of SHP in Caco-2 cells partially offset the bile acid mediated repression of ASBT promoter activity. In conclusion, the human ASBT is positively regulated by retinoic acid. Bile acids induce a negative feedback regulation of human ASBT via an FXR-mediated, SHP-dependent effect upon RAR/RXR activation of ASBT.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genome-wide association study of alcohol dependence implicates a region on chromosome 11. | 2010 | 20201924 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Adverse events associated with obeticholic acid: a real-world, pharmacovigilance study. | Zhang C et al. | β | 2025 | β |
| Association of bile acid diarrhea with symptoms and disease activity in Crohn's disease: post-hoc clinical trial analysis of serum 7a-hydroxy-4cholestern-3-one, C4, in patients with active Crohn's disease. | Battat R et al. | β | 2025 | β |
| Bile acid signaling in MASLD: From pathogenesis to therapeutic applications. | Simbrunner B et al. | β | 2025 | β |
| Bile acid and nonalcoholic steatohepatitis: Molecular insights and therapeutic targets. | Cheng Z et al. | β | 2024 | β |
| Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development. | Li T et al. | β | 2024 | β |
| Design and development of novel self-assembled catechol-modified bile acid conjugates as pH-responsive apical sodium-dependent bile acid transporter targeting nanoparticles. | Lee DN et al. | β | 2024 | β |
| Host response to cholestyramine can be mediated by the gut microbiota. | Newman NK et al. | β | 2024 | β |
| Intestinal stearoyl-CoA desaturase-1 regulates energy balance via alterations in bile acid homeostasis | Burchat N et al. | β | 2024 | β |
| <i>Clostridium scindens</i> exacerbates experimental necrotizing enterocolitis via upregulation of the apical sodium-dependent bile acid transporter. | Calton CM et al. | β | 2024 | β |
| Novel Expression of Apical Bile Acid Transport (ASBT) More Proximally Than Distal Ileum Contributing to Enhanced Intestinal Bile Acid Absorption in Obesity. | Sundaram S et al. | β | 2024 | β |
| Physical exercise plays a role in rebalancing the bile acids of enterohepatic axis in non-alcoholic fatty liver disease. | Zhang M et al. | β | 2024 | β |
| Potential role of bile acids in the pathogenesis of necrotizing enterocolitis. | Yang J et al. | β | 2024 | β |
| Retinoid X receptor heterodimers in hepatic function: structural insights and therapeutic potential. | Xu R et al. | β | 2024 | β |
| The gut microbiota-bile acid axis in cholestatic liver disease. | Sun D et al. | β | 2024 | β |
| The role of botanical triterpenoids and steroids in bile acid metabolism, transport, and signaling: Pharmacological and toxicological implications. | Luo Z et al. | β | 2024 | β |
| Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid. | van Hooff MC et al. | β | 2024 | β |
| Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis. | Meadows V et al. | β | 2023 | β |
| Regional Transcriptomics and Proteomics of Pharmacokinetics-Related Genes in Human Intestine. | Murata M et al. | β | 2023 | β |
| Steroid hormone signaling: What we can learn from insect models. | Okamoto N et al. | β | 2023 | β |
| The Crosstalk between Gut Microbiota and Bile Acids Promotes the Development of Non-Alcoholic Fatty Liver Disease. | Li Z et al. | β | 2023 | β |
| The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis. | Xiang D et al. | β | 2023 | β |
| A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARΞ±) and farnesoid X receptor (FXR). | Zhou S et al. | β | 2022 | β |
| Bile Acids-A Peek Into Their History and Signaling. | Nguyen JT et al. | β | 2022 | β |
| Gut microbiome and non-alcoholic fatty liver disease. | Purohit A et al. | β | 2022 | β |
| L-Arabinose improves hypercholesterolemia via regulating bile acid metabolism in high-fat-high-sucrose diet-fed mice. | Wang Y et al. | β | 2022 | β |
| Maralixibat: First Approval. | Shirley M | β | 2022 | β |
| Molecular Basis of Bile Acid-FXR-FGF15/19 Signaling Axis. | Katafuchi T et al. | β | 2022 | β |
| Odevixibat: an investigational inhibitor of the ileal bile acid transporter (IBAT) for the treatment of biliary atresia. | Laue T et al. | β | 2022 | β |
| Significance of the Vitamin D Receptor on Crosstalk with Nuclear Receptors and Regulation of Enzymes and Transporters. | Noh K et al. | β | 2022 | β |
| A Link between Intrahepatic Cholestasis and Genetic Variations in Intracellular Trafficking Regulators. | Li Q et al. | β | 2021 | β |
| Cholesterol-lowering effects of taurine through the reduction of ileal FXR signaling due to the alteration of ileal bile acid composition. | Miyata M et al. | β | 2021 | β |
| Deletion of Intestinal SHP Impairs Short-term Response to Cholic Acid Challenge in Male Mice. | Nguyen JT et al. | β | 2021 | β |
| Fxr signaling and microbial metabolism of bile salts in the zebrafish intestine. | Wen J et al. | β | 2021 | β |
| Network pharmacology-based mechanism prediction and pharmacological validation of Xiaoyan Lidan formula on attenuating alpha-naphthylisothiocyanate induced cholestatic hepatic injury in rats. | Wang M et al. | β | 2021 | β |
| Plasma Cell-Free DNA Methylomics of Bipolar Disorder With and Without Rapid Cycling. | Ho AM et al. | β | 2021 | β |
| Review article: therapeutic aspects of bile acid signalling in the gut-liver axis. | Simbrunner B et al. | β | 2021 | β |
| Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. | Radun R et al. | β | 2021 | β |
| The pathophysiological function of non-gastrointestinal farnesoid X receptor. | Yan N et al. | β | 2021 | β |
| The Role of FGF19 and MALRD1 in Enterohepatic Bile Acid Signaling. | Wang LX et al. | β | 2021 | β |
| The role of the retinoid receptor, RAR/RXR heterodimer, in liver physiology. | Li B et al. | β | 2021 | β |
| A <i>Villin</i>-Driven <i>Fxr</i> Transgene Modulates Enterohepatic Bile Acid Homeostasis and Response to an <i>n</i>-6-Enriched High-Fat Diet. | Wren SN et al. | β | 2020 | β |
| Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges. | Li M et al. | β | 2020 | β |
| ASBT(SLC10A2): A promising target for treatment of diseases and drug discovery. | Yang N et al. | β | 2020 | β |
| Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease. | Li T et al. | β | 2020 | β |
| Circadian rhythms and bile acid homeostasis: a comprehensive review. | Yu Z et al. | β | 2020 | β |
| Elevated Coefficient of Variation in Total Fecal Bile Acids Precedes Diagnosis of Necrotizing Enterocolitis. | Knapp S et al. | β | 2020 | β |
| Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology. | BrΓΈnden A et al. | β | 2020 | β |
| Hesperidin alleviates cholestasis via activation of the farnesoid X receptor in vitro and in vivo. | Zhang G et al. | β | 2020 | β |
| Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition. | Honda A et al. | β | 2020 | β |
| Bile Acid-Activated Receptors: A Review on FXR and Other Nuclear Receptors. | Shin DJ et al. | β | 2019 | β |
| Bile acid homeostasis in gastrointestinal and metabolic complications of cystic fibrosis. | van de Peppel IP et al. | β | 2019 | β |
| Changes in Enterohepatic Circulation after Duodenal-Jejunal Bypass and Reabsorption of Bile Acids in the Bilio-Pancreatic Limb. | Ise I et al. | β | 2019 | β |
| Defective FXR-FGF15 signaling and bile acid homeostasis in cystic fibrosis mice can be restored by the laxative polyethylene glycol. | Bertolini A et al. | β | 2019 | β |
| Intestinal Absorption of Bile Acids in Health and Disease. | Ticho AL et al. | β | 2019 | β |
| Mechanism of Dyslipidemia in Obesity-Unique Regulation of Ileal Villus Cell Brush Border Membrane Sodium-Bile Acid Cotransport. | Sundaram S et al. | β | 2019 | β |
| New therapeutic options for bile acid malabsorption diarrhea. | Valencia-RodrΓguez A et al. | β | 2019 | β |
| Targeting FXR in Cholestasis. | Keitel V et al. | β | 2019 | β |
| Tyrosine Phosphorylation Regulates Plasma Membrane Expression and Stability of the Human Bile Acid Transporter ASBT (<i>SLC</i>10<i>A</i>2). | Chothe PP et al. | β | 2019 | β |
| Ursodeoxycholic acid accelerates bile acid enterohepatic circulation. | Zhang Y et al. | β | 2019 | β |
| An extract from date palm fruit (Phoenix dactylifera) acts as a co-agonist ligand for the nuclear receptor FXR and differentially modulates FXR target-gene expression in vitro. | Alfaro-Viquez E et al. | β | 2018 | β |
| ApoE is a major determinant of hepatic bile acid homeostasis in mice. | von Hardenberg S et al. | β | 2018 | β |
| Effects of dietary pectin on the profile and transport of intestinal bile acids in young pigs. | Fang W et al. | β | 2018 | β |
| Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases. | Chen HL et al. | β | 2018 | β |
| Natural products as modulators of the nuclear receptors and metabolic sensors LXR, FXR and RXR. | Hiebl V et al. | β | 2018 | β |
| Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations. | Cariello M et al. | β | 2018 | β |
| Nuclear Receptor Metabolism of Bile Acids and Xenobiotics: A Coordinated Detoxification System with Impact on Health and Diseases. | Garcia M et al. | β | 2018 | β |
| Organic Solute Transporter Ξ±-Ξ² Protects Ileal Enterocytes From Bile Acid-Induced Injury. | Ferrebee CB et al. | β | 2018 | β |
| Placebo-Controlled Randomized Trial of an Intestinal Bile Salt Transport Inhibitor for Pruritus in Alagille Syndrome. | Shneider BL et al. | β | 2018 | β |
| An important intestinal transporter that regulates the enterohepatic circulation of bile acids and cholesterol homeostasis: The apical sodium-dependent bile acid transporter (SLC10A2/ASBT). | Xiao L et al. | β | 2017 | β |
| Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. | ChΓ‘vez-Talavera O et al. | β | 2017 | β |
| Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal inΒ vitro cell models. | Zhang Y et al. | β | 2017 | β |
| The interrelationship between bile acid and vitamin A homeostasis. | Saeed A et al. | β | 2017 | β |
| Western Diet Deregulates Bile Acid Homeostasis, Cell Proliferation, and Tumorigenesis in Colon. | Dermadi D et al. | β | 2017 | β |
| Chemically modified peptides and proteins - critical considerations for oral delivery. | Buckley ST et al. | β | 2016 | β |
| Farnesoid X receptor as a regulator of fuel consumption and mitochondrial function. | Han CY et al. | β | 2016 | β |
| HDL functionality in reverse cholesterol transport--Challenges in translating data emerging from mouse models to human disease. | Lee-Rueckert M et al. | β | 2016 | β |
| Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis. | Milkiewicz M et al. | β | 2016 | β |
| Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules. | Copple BL et al. | β | 2016 | β |
| Trimethylamine-N-oxide: a link between the gut microbiome, bile acid metabolism, and atherosclerosis. | Wilson A et al. | β | 2016 | β |
| Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer. | Li T et al. | β | 2015 | β |
| Chronic activation of FXR in transgenic mice caused perinatal toxicity and sensitized mice to cholesterol toxicity. | Cheng Q et al. | β | 2015 | β |
| Farnesoid x receptor in human metabolism and disease: the interplay between gene polymorphisms, clinical phenotypes and disease susceptibility. | Koutsounas I et al. | β | 2015 | β |
| Intestinal nuclear receptors in HDL cholesterol metabolism. | Degirolamo C et al. | β | 2015 | β |
| N-glycosylation is essential for ileal ASBT function and protection against proteases. | Muthusamy S et al. | β | 2015 | β |
| Short-term circadian disruption impairs bile acid and lipid homeostasis in mice. | Ferrell JM et al. | β | 2015 | β |
| The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. | Verbeke L et al. | β | 2015 | β |
| A novel RARΞ±/CAR-mediated mechanism for regulation of human organic solute transporter-Ξ² gene expression. | Xu S et al. | β | 2014 | β |
| A single element in the 3'UTR of the apical sodium-dependent bile acid transporter controls both stabilization and destabilization of mRNA. | Soler DM et al. | β | 2014 | β |
| Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer. | Tsuei J et al. | β | 2014 | β |
| Bile acid signaling in metabolic disease and drug therapy. | Li T et al. | β | 2014 | β |
| c-Fos mediates repression of the apical sodium-dependent bile acid transporter by fibroblast growth factor-19 in mice. | Ghosh A et al. | β | 2014 | β |
| Coordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 Diabetes. | Ding L et al. | β | 2014 | β |
| Homologue gene of bile acid transporters ntcp, asbt, and ost-alpha in rainbow trout Oncorhynchus mykiss: tissue expression, effect of fasting, and response to bile acid administration. | Murashita K et al. | β | 2014 | β |
| Inflammatory bowel disease alters intestinal bile acid transporter expression. | Jahnel J et al. | β | 2014 | β |
| OstΞ±-/- mice exhibit altered expression of intestinal lipid absorption genes, resistance to age-related weight gain, and modestly improved insulin sensitivity. | Wheeler SG et al. | β | 2014 | β |
| Resveratrol promotes degradation of the human bile acid transporter ASBT (SLC10A2). | Chothe PP et al. | β | 2014 | β |
| Bile acids: from digestion to cancers. | Baptissart M et al. | β | 2013 | β |
| Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. | Ridlon JM et al. | β | 2013 | β |
| Developments in understanding bile acid metabolism. | Morimoto K et al. | β | 2013 | β |
| FXR signaling in the enterohepatic system. | Matsubara T et al. | β | 2013 | β |
| Nuclear-receptor-mediated regulation of drug- and bile-acid-transporter proteins in gut and liver. | Staudinger JL et al. | β | 2013 | β |
| Nuclear receptors in bile acid metabolism. | Li T et al. | β | 2013 | β |
| Nutritional lipidomics: molecular metabolism, analytics, and diagnostics. | Smilowitz JT et al. | β | 2013 | β |
| Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. | Zhang JH et al. | β | 2013 | β |
| Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. | Hollman DA et al. | β | 2012 | β |
| Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease. | Attinkara R et al. | β | 2012 | β |
| Enterobacteria-mediated deconjugation of taurocholic acid enhances ileal farnesoid X receptor signaling. | Kuribayashi H et al. | β | 2012 | β |
| FXR and PXR: potential therapeutic targets in cholestasis. | Jonker JW et al. | β | 2012 | β |
| Enterobacteria modulate intestinal bile acid transport and homeostasis through apical sodium-dependent bile acid transporter (SLC10A2) expression. | Miyata M et al. | β | 2011 | β |
| Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. | Claudel T et al. | β | 2011 | β |
| Role of nuclear receptor SHP in metabolism and cancer. | Zhang Y et al. | β | 2011 | β |
| Role of peripheral serotonin in glucose and lipid metabolism. | Watanabe H et al. | β | 2011 | β |
| Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. | Swann JR et al. | β | 2011 | β |
| Apical sodium-dependent bile acid transporter upregulation is associated with necrotizing enterocolitis. | Halpern MD et al. | β | 2010 | β |
| ATPase Class I Type 8B Member 1 and protein kinase C zeta induce the expression of the canalicular bile salt export pump in human hepatocytes. | Chen F et al. | β | 2010 | β |
| Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease. | Gadaleta RM et al. | β | 2010 | β |
| Bile acids: short and long term effects in the intestine. | Bajor A et al. | β | 2010 | β |
| Deciphering the nuclear bile acid receptor FXR paradigm. | Modica S et al. | β | 2010 | β |
| Genome-wide association study of alcohol dependence implicates a region on chromosome 11. | Edenberg HJ et al. | β | 2010 | β |
| Peripheral serotonin enhances lipid metabolism by accelerating bile acid turnover. | Watanabe H et al. | β | 2010 | β |
| Bile acids inhibit duodenal secretin expression via orphan nuclear receptor small heterodimer partner (SHP). | Lam IP et al. | β | 2009 | β |
| Bile acid transporters. | Dawson PA et al. | β | 2009 | β |
| Cholesterol feeding prevents hepatic accumulation of bile acids in cholic acid-fed farnesoid X receptor (FXR)-null mice: FXR-independent suppression of intestinal bile acid absorption. | Miyata M et al. | β | 2009 | β |
| Expression and regulation of the bile acid transporter, OSTalpha-OSTbeta in rat and human intestine and liver. | Khan AA et al. | β | 2009 | β |
| Hepatocyte nuclear factor-4alpha and bile acids regulate human concentrative nucleoside transporter-1 gene expression. | Klein K et al. | β | 2009 | β |
| Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators? | Beuers U et al. | β | 2009 | β |
| Mutation screening of apical sodium-dependent bile acid transporter (SLC10A2): novel haplotype block including six newly identified variants linked to reduced expression. | Renner O et al. | β | 2009 | β |
| OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids. | Ballatori N et al. | β | 2009 | β |
| Role of bile acids and bile acid receptors in metabolic regulation. | Lefebvre P et al. | β | 2009 | β |
| A translational view on the biliary lipid secretory network. | Lo Sasso G et al. | β | 2008 | β |
| beta-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes. | Sinha J et al. | β | 2008 | β |
| Bile acid transporters in health and disease. | Kosters A et al. | β | 2008 | β |
| Cytosolic half of transmembrane domain IV of the human bile acid transporter hASBT (SLC10A2) forms part of the substrate translocation pathway. | Khantwal CM et al. | β | 2008 | β |
| Does abnormal bile acid metabolism contribute to NEC? | Halpern MD et al. | β | 2008 | β |
| Endocrine and paracrine role of bile acids. | Keitel V et al. | β | 2008 | β |
| Exploring possible mechanisms for primary bile acid malabsorption: evidence for different regulation of ileal bile acid transporter transcripts in chronic diarrhoea. | Balesaria S et al. | β | 2008 | β |
| [Functional analysis of nuclear receptor FXR controlling metabolism of cholesterol]. | Ohno M | β | 2008 | β |
| Intestinal bile acid physiology and pathophysiology. | Martinez-Augustin O et al. | β | 2008 | β |
| Molecular basis of endocrine regulation by orphan nuclear receptor Small Heterodimer Partner. | Chanda D et al. | β | 2008 | β |
| Nuclear hormone receptor-dependent regulation of hepatic transporters and their role in the adaptive response in cholestasis. | Stahl S et al. | β | 2008 | β |
| Reduced ileal expression of OSTalpha-OSTbeta in non-obese gallstone disease. | Renner O et al. | β | 2008 | β |
| The Caco-2 cell monolayer: usefulness and limitations. | Sun H et al. | β | 2008 | β |
| The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. | Frankenberg T et al. | β | 2008 | β |
| The role of FXR in disorders of bile acid homeostasis. | Eloranta JJ et al. | β | 2008 | β |
| Transactivation of the human apical sodium-dependent bile acid transporter gene by human serum. | Duane WC et al. | β | 2008 | β |
| Bile acid transporters: structure, function, regulation and pathophysiological implications. | Alrefai WA et al. | β | 2007 | β |
| Effects of bile acids on expression of the human apical sodium dependent bile acid transporter gene. | Duane WC et al. | β | 2007 | β |
| Inhibition of the intestinal absorption of bile acids using cationic derivatives: mechanism and repercussions. | Vicens M et al. | β | 2007 | β |
| Review article: The function and regulation of proteins involved in bile salt biosynthesis and transport. | Pellicoro A et al. | β | 2007 | β |
| Structure and function of the atypical orphan nuclear receptor small heterodimer partner. | Lee YS et al. | β | 2007 | β |
| Targeting farnesoid X receptor for liver and metabolic disorders. | Fiorucci S et al. | β | 2007 | β |
| Taurodeoxycholate modulates apical Cl-/OH- exchange activity in Caco2 cells. | Alrefai WA et al. | β | 2007 | β |
| Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation. | Demeilliers C et al. | β | 2006 | β |
| Analysis of ileal sodium/bile acid cotransporter and related nuclear receptor genes in a family with multiple cases of idiopathic bile acid malabsorption. | Montagnani M et al. | β | 2006 | β |
| Apical sodium bile acid transporter and ileal lipid binding protein in gallstone carriers. | Bergheim I et al. | β | 2006 | β |
| Bile acids induce ileal damage during experimental necrotizing enterocolitis. | Halpern MD et al. | β | 2006 | β |
| c-Fos is a critical mediator of inflammatory-mediated repression of the apical sodium-dependent bile acid transporter. | Neimark E et al. | β | 2006 | β |
| Cholesterol dependent downregulation of mouse and human apical sodium dependent bile acid transporter (ASBT) gene expression: molecular mechanism and physiological consequences. | Thomas C et al. | β | 2006 | β |
| FXR, a multipurpose nuclear receptor. | Lee FY et al. | β | 2006 | β |
| FXR: a target for cholestatic syndromes? | Cai SY et al. | β | 2006 | β |
| Hepatobiliary transporters and drug-induced cholestasis. | Pauli-Magnus C et al. | β | 2006 | β |
| International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. | Moore DD et al. | β | 2006 | β |
| LXRS and FXR: the yin and yang of cholesterol and fat metabolism. | Kalaany NY et al. | β | 2006 | β |
| Regulation of the mouse organic solute transporter alpha-beta, Ostalpha-Ostbeta, by bile acids. | Frankenberg T et al. | β | 2006 | β |
| Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. | Zollner G et al. | β | 2006 | β |
| The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. | Swales KE et al. | β | 2006 | β |
| The human Na+-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanism. | Eloranta JJ et al. | β | 2006 | β |
| The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. | Landrier JF et al. | β | 2006 | β |
| The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships. | Geyer J et al. | β | 2006 | β |
| Transactivation of rat apical sodium-dependent bile acid transporter and increased bile acid transport by 1alpha,25-dihydroxyvitamin D3 via the vitamin D receptor. | Chen X et al. | β | 2006 | β |
| Cholesterol modulates human intestinal sodium-dependent bile acid transporter. | Alrefai WA et al. | β | 2005 | β |
| Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. | Eloranta JJ et al. | β | 2005 | β |
| Coordinate transcriptional regulation of transport and metabolism. | Eloranta JJ et al. | β | 2005 | β |
| Enterohepatic transport of bile salts and genetics of cholestasis. | Pauli-Magnus C et al. | β | 2005 | β |
| FTF and LRH-1, two related but different transcription factors in human Caco-2 cells: their different roles in the regulation of bile acid transport. | Pan DH et al. | β | 2005 | β |
| Hepatocellular transporters and cholestasis. | Pauli-Magnus C et al. | β | 2005 | β |
| The type 4 subfamily of P-type ATPases, putative aminophospholipid translocases with a role in human disease. | Paulusma CC et al. | β | 2005 | β |